You’ll hear a lot from companies about ‘corporate social responsibility’ and various schemes and initiatives they like to support. Price Perrott has made a specific commitment aimed at supporting innovation into a cure for Multiple Sclerosis amongst researchers in the field.
The UK Multiple Sclerosis Society aims to support people affected by MS and promote research into a cure for MS. Established in memory of Rosemary Anne Price, this research award provides a bursary to two nominated research students working in Multiple Sclerosis. It helps them with the costs associated in attending the bi-annual UK “MS Frontiers” conference.
We are delighted that Price Perrott is supporting the MS Society with The Rosemary Anne Price MS Research Award. Attending our 'MS Frontiers' event will be highly valuable to a student involved in the vital work to develop improved treatments and ultimately a cure for MS.
If you are a UK researcher in the field who would like to apply for this funding, or you’d like to follow our commitment in supporting MS by making a donation to fund this award, please contact Catherine Royall at the UK Multiple Sclerosis Society for more information.
Elena's research at the University of Nottingham Clinical Neurology Group involved an MS Frontiers session entitled 'EBV infection empowers human B cells for autoimmunity - Role of autophagy and relevance to multiple sclerosis.' Her work studying the Epstein Barr Virus (EBV) infection may provide insights into the progression of MS.
Grace presented a poster session on Immunopathology entitled "Natural killer cell subsets and the pathogenesis of MS." Her work at Imperial College London is contributing to understanding the role of immune cell interactions in MS relapse.
Sybil Stacpoole won a 2011 award with her response that
"I am putting MS on the map by using human embryonic stem cells and low oxygen conditions found physiologically in the brain to investigate what drives stem cells to become oligodendrocytes and mature to make myelin sheaths, searching for new approaches to stimulate remyelination and provide therapeutic options for the unmet need of patients with secondary progressive MS. "
Sagar Sedani received a 2011 award for his response that "I am putting MS on the map by doing my biomedical sciences dissertation on paediatric MS and submitting it to MS Frontiers. About 5-10% of young MS adults have childhood symptoms, and I am examining diagnostic criteria for early diagnosis, treatment and outcome. I have also helped to fundraise £2000 for MS research."